News

Provost Michael Kotlikoff led a panel of faculty and community partners Oct. 20 to discuss collaborative work and community efforts that engage students in addressing local and global public health challenges, including issues of food insecurity and health equity.

Transplanting young blood vessel cells into older mice can make their aged stem cells take on the characteristics of young stem cells, leading to healthier blood systems and promoting better recovery from cancer treatment side effects, according to new research from Weill Cornell Medicine.

Women diagnosed with an infectious parasitic disease prevalent in sub-Saharan Africa are at increased risk of contracting human immunodeficiency virus (HIV), and both men and women who had this parasitic disease developed higher HIV viral loads after becoming HIV-infected, according to a study from Weill Cornell Medicine investigators.

A new therapy that uses blood-vessel-lining cells to regenerate damaged tissue has the potential to treat liver cirrhosis, Weill Cornell Medicine scientists demonstrate in new research.

In an age of overabundant and accessible information, when evidence-based research is devalued, how can scientists and journalists work in concert to rightfully inform the public of medical progress?

The goal of the Dean’s Inaugural Symposium on Opportunities for Entrepreneurship and Academic Drug Development, hosted at Weill Cornell Medicine’s Uris Auditorium, was to highlight the resources available to investigators to help them turn their research findings into new treatments and therapies for patients.

When Dr. Onyinye Balogun was a young girl, her father’s only sister was diagnosed with breast cancer back home in their native Nigeria. Dr. Balogun had recently immigrated to the United States with her parents, but on a return visit the severity of her aunt’s disease became clear.

Dr. Virginia Pascual, the Drukier Director of the Gale and Ira Drukier Institute for Children’s Health at Weill Cornell Medicine, was awarded the Lupus Insight Prize on June 15 by the Lupus Research Alliance. 

A hospital in India founded by one of Weill Cornell Medicine’s first female alumni is a ‘transformative’ destination for today’s global health students

Menopause causes metabolic changes in the brain that may increase the risk of Alzheimer’s disease.

Last spring, veteran pharmaceutical executive and entrepreneur Dr. William Polvino was tapped as CEO of Bridge Medicines, a company established in October 2016 to further the development of drugs nurtured by the Tri-Institutional Therapeutics Discovery Institute. 

Endocrinologist Jason Baker can uniquely relate to his patients: Like them, he lives with type 1 diabetes. Now, he’s doing all that he can to make a difference in the lives of his patients in New York and the developing world.

Weill Cornell Medicine has received a $45.3 million renewal grant from the National Institutes of Health’s Clinical and Translational Science Awards Program to continue funding its multi-institutional Clinical and Translational Science Center until 2022.

Dr. Michael LeVine, (PhD ’16), grew up in Taunton, Massachusetts, a city about 40 miles south of Boston. One of the oldest towns in the United States — founded in the 1630s — Taunton in recent decades has suffered through a very modern scourge: the staggering opioid epidemic that has devastated so many communities nationwide.

Internationally renowned neuro-oncologist Dr. Howard A. Fine of Weill Cornell Medicine and NewYork-Presbyterian will receive a five-year, $6 million National Institutes of Health Director’s Pioneer Award for brain cancer research.

Awards, honors, prizes and achievements for the month of September.

The new Roosevelt Island campus of Cornell Tech has catalyzed a slew of innovative academic programs that will benefit not only Cornell Tech students but also students from the Ithaca campus. And those programs will deepen the symbiotic academic partnership that links Cornell’s New York state campuses, administrators say.

Though medicine has made important strides in treating cardiac patients in recent years, there’s still no cure for cardiovascular disease — a broad group of disorders that claim nearly 18 million lives around the globe annually, a number that the World Health Organization predicts will grow to almost 23.6 million by 2030.

The complex life cycle of the parasite that causes malaria has made it a difficult foe to beat. But new insights on how the parasite is transmitted from humans to the mosquitoes that spread malaria may lead to new ways to control this deadly disease.